Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]
Discontinued
Reference number: GID-TA10309
Following on from information provided to NICE by the company in July 2020 the appraisal of Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.